GlassScriptPhysician profile
Neri Franzon
NPI 1366629370
$8,697.52
in general payments reported to CMS, 2019-2025
28 companies · $557 in 2025
The $557 reported for 2025 was more than what 77% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,868 · 2020: $698 · 2021: $2,125 · 2022: $1,209 · 2023: $1,034 · 2024: $1,207 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,575.38 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $833.10 | 2019-2025 | Xifaxan |
| Abbvie INC. | $790.33 | 2021-2024 | |
| Lilly USA, LLC | $730.92 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $711.76 | 2019-2025 | Otezla, Otezla, Repatha |
| Allergan, INC. | $283.30 | 2019-2020 | |
| Heartflow, INC. | $264.72 | 2023-2024 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.36 | 2019-2021 | |
| Galderma Laboratories, L.P. | $189.39 | 2019-2024 | |
| Glaxosmithkline, LLC. | $180.71 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $154.07 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $139.58 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $128.28 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $96.16 | 2019 | |
| Horizon Therapeutics Plc | $53.31 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $52.26 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Paratek Pharmaceuticals, INC. | $33.55 | 2022-2025 | Xhance, Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $27.78 | 2022 | |
| Eisai INC. | $27.12 | 2020-2021 | |
| Astellas Pharma US INC | $26.66 | 2025 | Veozah |
| Jazz Pharmaceuticals INC. | $23.86 | 2022 | |
| Almatica Pharma LLC | $20.87 | 2024 | Loreev Xr |
| Biohaven Pharmaceuticals, INC. | $20.80 | 2021 | |
| Adlon Therapeutics L.P. | $20.63 | 2019 | |
| Novo Nordisk INC | $19.85 | 2023 | |
| Exact Sciences Corporation | $18.04 | 2024 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $14.95 | 2022 | |
| Shield Therapeutics INC | $14.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neri Franzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.